IN2014MN02644A - - Google Patents
Info
- Publication number
- IN2014MN02644A IN2014MN02644A IN2644MUN2014A IN2014MN02644A IN 2014MN02644 A IN2014MN02644 A IN 2014MN02644A IN 2644MUN2014 A IN2644MUN2014 A IN 2644MUN2014A IN 2014MN02644 A IN2014MN02644 A IN 2014MN02644A
- Authority
- IN
- India
- Prior art keywords
- compound
- amorphous
- crystalline
- aza
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655934P | 2012-06-05 | 2012-06-05 | |
| US201361759295P | 2013-01-31 | 2013-01-31 | |
| US13/800,374 US8969588B2 (en) | 2012-06-05 | 2013-03-13 | Solid forms of an antiviral compound |
| PCT/US2013/044138 WO2013184698A1 (en) | 2012-06-05 | 2013-06-04 | Solid forms of an antiviral compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02644A true IN2014MN02644A (es) | 2015-10-16 |
Family
ID=49670993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2644MUN2014 IN2014MN02644A (es) | 2012-06-05 | 2013-06-04 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8969588B2 (es) |
| EP (1) | EP2855478B1 (es) |
| JP (2) | JP2015518891A (es) |
| KR (1) | KR20150028971A (es) |
| CN (2) | CN104379584A (es) |
| AR (1) | AR091259A1 (es) |
| AU (1) | AU2013271768B2 (es) |
| BR (1) | BR112014030400A2 (es) |
| CA (1) | CA2875507A1 (es) |
| ES (1) | ES2694759T3 (es) |
| HK (1) | HK1205127A1 (es) |
| IL (1) | IL236004A0 (es) |
| IN (1) | IN2014MN02644A (es) |
| MX (1) | MX2014014563A (es) |
| PT (1) | PT2855478T (es) |
| RU (1) | RU2014150437A (es) |
| SG (1) | SG11201408013WA (es) |
| TW (1) | TW201408661A (es) |
| UY (1) | UY34844A (es) |
| WO (1) | WO2013184698A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| KR101546119B1 (ko) | 2009-05-13 | 2015-08-20 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| CN104244945B (zh) | 2011-09-16 | 2016-08-31 | 吉利德制药有限责任公司 | 用于治疗hcv的方法 |
| US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| DK2950786T3 (da) | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| ES2792503T3 (es) | 2013-08-27 | 2020-11-11 | Gilead Pharmasset Llc | Formulación combinada de dos compuestos antivirales |
| CN104513223B (zh) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
| WO2016128453A1 (en) | 2015-02-13 | 2016-08-18 | Sandoz Ag | Pharmaceutical compositions comprising ledipasvir and sofosbuvir |
| WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
| CN104788361B (zh) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法 |
| WO2016193919A1 (en) | 2015-06-05 | 2016-12-08 | Mylan Laboratories Limited | Polymorphic form of ledipasvir |
| CN104961733B (zh) * | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | 雷迪帕韦晶型及其制备方法 |
| WO2017072596A1 (en) * | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
| CN106608870A (zh) * | 2015-10-26 | 2017-05-03 | 广东东阳光药业有限公司 | 一种制备雷迪帕韦杂质的方法 |
| WO2017072714A1 (en) | 2015-10-30 | 2017-05-04 | Lupin Limited | Stable ledipasvir premix and process of preparation thereof |
| CN105237517B (zh) * | 2015-10-30 | 2017-10-27 | 南京正大天晴制药有限公司 | 结晶的雷迪帕韦化合物及其制备方法 |
| CN105237384B (zh) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | 一种多取代芴衍生物的制备方法 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN106008316B (zh) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | 一种合成雷迪帕韦手性中间体的方法 |
| CN106699740A (zh) * | 2016-12-26 | 2017-05-24 | 上海博志研新药物技术有限公司 | 一种雷迪帕韦和索非布韦复方片剂及其制备方法和应用 |
| US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
| CN109053400A (zh) * | 2018-08-24 | 2018-12-21 | 江苏工程职业技术学院 | 一种雷迪帕韦关键中间体的制备方法 |
| US11378965B2 (en) | 2018-11-15 | 2022-07-05 | Toyota Research Institute, Inc. | Systems and methods for controlling a vehicle based on determined complexity of contextual environment |
| CN109678686A (zh) * | 2018-12-19 | 2019-04-26 | 江苏工程职业技术学院 | 一种抗丙肝药物雷迪帕韦关键中间体的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US6482847B2 (en) * | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
| US20070129385A1 (en) * | 2003-08-28 | 2007-06-07 | Sharma Mukesh K | Amorphous valganciclovir hydrochloride |
| CN100448879C (zh) * | 2004-07-22 | 2009-01-07 | 北京化工大学 | 一种无定型头孢呋辛酯的制备方法 |
| US20100076047A1 (en) * | 2007-08-20 | 2010-03-25 | Sankar Reddy Budidet | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt |
| KR20100031045A (ko) * | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | 아데포비어 디피복실의 정제방법 |
| KR101546119B1 (ko) | 2009-05-13 | 2015-08-20 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| EP2432788A1 (en) * | 2009-05-20 | 2012-03-28 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
| JPWO2011046182A1 (ja) * | 2009-10-16 | 2013-03-07 | 出光興産株式会社 | 含フルオレン芳香族化合物、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子 |
| UY33445A (es) | 2010-06-10 | 2012-01-31 | Gilead Sciences Inc | Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit |
| MX2014008008A (es) * | 2011-12-29 | 2014-08-21 | Abbvie Inc | Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c. |
| US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| DK2950786T3 (da) * | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
-
2013
- 2013-03-13 US US13/800,374 patent/US8969588B2/en active Active
- 2013-05-31 TW TW102119443A patent/TW201408661A/zh unknown
- 2013-06-03 AR ARP130101956 patent/AR091259A1/es unknown
- 2013-06-03 UY UY0001034844A patent/UY34844A/es not_active Application Discontinuation
- 2013-06-04 MX MX2014014563A patent/MX2014014563A/es unknown
- 2013-06-04 JP JP2015516143A patent/JP2015518891A/ja active Pending
- 2013-06-04 CA CA2875507A patent/CA2875507A1/en not_active Abandoned
- 2013-06-04 IN IN2644MUN2014 patent/IN2014MN02644A/en unknown
- 2013-06-04 RU RU2014150437A patent/RU2014150437A/ru not_active Application Discontinuation
- 2013-06-04 AU AU2013271768A patent/AU2013271768B2/en not_active Ceased
- 2013-06-04 CN CN201380032193.2A patent/CN104379584A/zh active Pending
- 2013-06-04 SG SG11201408013WA patent/SG11201408013WA/en unknown
- 2013-06-04 KR KR20147037165A patent/KR20150028971A/ko not_active Application Discontinuation
- 2013-06-04 ES ES13729569.7T patent/ES2694759T3/es active Active
- 2013-06-04 BR BR112014030400A patent/BR112014030400A2/pt not_active Application Discontinuation
- 2013-06-04 PT PT13729569T patent/PT2855478T/pt unknown
- 2013-06-04 EP EP13729569.7A patent/EP2855478B1/en active Active
- 2013-06-04 WO PCT/US2013/044138 patent/WO2013184698A1/en active Application Filing
- 2013-06-04 CN CN201510929740.8A patent/CN105524050A/zh active Pending
-
2014
- 2014-11-30 IL IL236004A patent/IL236004A0/en unknown
-
2015
- 2015-01-20 US US14/600,911 patent/US9139570B2/en active Active
- 2015-06-23 HK HK15105959.1A patent/HK1205127A1/xx unknown
- 2015-08-13 US US14/825,386 patent/US9682987B2/en active Active
-
2017
- 2017-04-19 JP JP2017083097A patent/JP2017128605A/ja active Pending
- 2017-05-26 US US15/607,326 patent/US20170327488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014030400A2 (pt) | 2016-06-07 |
| US9139570B2 (en) | 2015-09-22 |
| CN104379584A (zh) | 2015-02-25 |
| RU2014150437A (ru) | 2016-08-10 |
| US20170327488A1 (en) | 2017-11-16 |
| EP2855478A1 (en) | 2015-04-08 |
| AU2013271768B2 (en) | 2018-05-17 |
| US20130324496A1 (en) | 2013-12-05 |
| CN105524050A (zh) | 2016-04-27 |
| US8969588B2 (en) | 2015-03-03 |
| US9682987B2 (en) | 2017-06-20 |
| IL236004A0 (en) | 2015-02-01 |
| SG11201408013WA (en) | 2015-01-29 |
| WO2013184698A1 (en) | 2013-12-12 |
| US20150141659A1 (en) | 2015-05-21 |
| HK1205127A1 (en) | 2015-12-11 |
| JP2017128605A (ja) | 2017-07-27 |
| EP2855478B1 (en) | 2018-08-08 |
| PT2855478T (pt) | 2018-11-21 |
| ES2694759T3 (es) | 2018-12-27 |
| CA2875507A1 (en) | 2013-12-12 |
| AR091259A1 (es) | 2015-01-21 |
| JP2015518891A (ja) | 2015-07-06 |
| UY34844A (es) | 2013-12-31 |
| US20150344488A1 (en) | 2015-12-03 |
| KR20150028971A (ko) | 2015-03-17 |
| AU2013271768A1 (en) | 2015-01-15 |
| TW201408661A (zh) | 2014-03-01 |
| MX2014014563A (es) | 2015-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02644A (es) | ||
| PH12015502839A1 (en) | Antiviral compounds | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| WO2012082672A3 (en) | Process and intermediates for preparing macrolactams | |
| IL229193A0 (en) | The history of pyridine-2--(h1) and its effectiveness as drugs for the treatment of myeloproliferative disorders, graft rejection, and infectious and immune-mediated diseases | |
| IL214449A0 (en) | Systems and methods for maintaining the dominance and increasing the bimoss production of nannochloropsis in an algae cultivation system | |
| MX2014001945A (es) | Procedimiento e intermedios para la preparacion de macrolactamas. | |
| ZA201206168B (en) | A process for the enzymatic synthesis of fatty acid alkyl esters | |
| MX336347B (es) | Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco. | |
| MX2015003124A (es) | Formas polimorficas de enzalutamida y su preparacion. | |
| MX339533B (es) | Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp). | |
| ZA201403678B (en) | Methods and systems for growing plants using silicate-based substrates,cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives ,and formulations,processes and systems for the same | |
| EP2729452A4 (en) | PROCESS FOR THE PREPARATION OF A POROUS ORGANIC METAL-COMPOUND POROUS STRUCTURE BASED ON ZINC METHYLIMIDAZOLATE | |
| EP2484673A3 (en) | A process for the resolution of (R,S)-nicotine | |
| MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
| PL2691362T3 (pl) | Mieszaniny estrów kwasu bursztynowego jako środek zmiękczający | |
| WO2011050095A3 (en) | Prevention and treatment of post-operative cognitive dysfunction (pocd) | |
| IL233132A0 (en) | Process for the preparation of esters of 5-fluoro-2-methyl-3-quinoline-2-ylmethylindol-1-yl-acetic acid | |
| IN2014MN02467A (es) | ||
| MX353863B (es) | Metodo para preparar una forma solida de acido acetico y productos de la misma. | |
| MX2014004083A (es) | Metodo para aislar ingenol. | |
| EP2695887A4 (en) | NEW RUTHENIUM COMPLEX AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOL COMPOUND USING AS CATALYST | |
| WO2014018679A3 (en) | Nme variant species expression and suppression | |
| IN2014DN00137A (es) | ||
| WO2012159981A3 (en) | PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS |